April 5, 2019
- Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 22, 2019
- Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 12, 2019
- Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 11, 2019
- Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
March 7, 2019
- Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
March 6, 2019
- Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock
March 4, 2019
- Apellis Pharmaceuticals to Present at the Cowen 39th Annual Health Care Conference
March 4, 2019
- Apellis Resumes Dosing in Its Phase 3 Program for Patients with Geographic Atrophy
February 28, 2019
- Apellis Pharmaceuticals Announces Collaboration with SFJ Pharmaceuticals® for APL-2 in Hematologic Indications
February 26, 2019
- Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
Displaying 1 - 10 of 58 results
